ACCD — Accolade Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Accolade, fiscal year end - February 29th, USD millions except per share, conversion factor applied.

	2020 February 29th	2021 February 28th	2022 February 28th	2023 February 28th	2024 February 29th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	133	170	310	363	414
Cost of Revenue
Gross Profit	58.8	76.7	141	164	193
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	181	217	436	827	529
Operating Profit	-48.2	-46.8	-126	-464	-114
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-51.2	-50.6	-129	-463	-98.6
Provision for Income Taxes
Net Income After Taxes	-51.4	-50.7	-123	-460	-99.8
Net Income Before Extraordinary Items
Net Income	-51.4	-50.7	-123	-460	-99.8
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-51.4	-50.7	-123	-460	-99.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.09	-1.72	-1.79	-3.64	-1.32
Dividends per Share